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Introduction
Recent advances in diagnostic techniques such as next-generation sequencing and whole exome sequencing (WES) have identified a variety of genetic disorders and related variants.
The identification of causative genes in pediatric patients with suspected genetic disorders is important to make a decision of timely treatment and predict its consequence. In particular, in case of lethal genetic disorder, parents and clinicians have to reach a consensus on the type of treatment, active or conservative.
To date, more than 6300 genetic disorders and 4000 genes have been established on a molecular basis with the help of WES, and the numbers are still growing (1, 2) . Diagnostic yield was shown to vary according to the patient's phenotype, sample size, and cohort characteristics, while the average diagnostic rate of WES reported by various institutions is about 40% (3) (4) (5) (6) (7) (8) (9) (10) .
It is time-consuming and challenging for clinical geneticist and bioinformatics to match a large number of candidate variants with diverse clinical symptoms (11) . In addition, the lack of supporting data leaves many variants as those of uncertain significance, leading to a number of questions to patients as well as clinicians (12). To address the issue, medical practitioners use several bioinformatic tools to establish prioritized variants, in accordance with the guideline of American College of Medical Genetics (ACMG) (13, 14) . These tools still have limitations in accurately predicting the possible clinical effects of each variant. Phenovar, an interpretation tool developed in 2014, first calculated a patient-specific diagnostic score for each Online Mendelian Inheritance in Man (OMIM) entry, which is assigned to each given variant (3) .
Although this has noticeably reduced the number of prioritized variants, the diagnosis rate is about 35%, not significantly different from that of previous studies (4) .
In order to improve diagnostic yield, we first took advantage of artificial intelligence technology to extract a rich pool of data on the pathogenicity of variants from scientific 5 literatures. Then we built a streamlined variant interpretation software, which conducts under few minutes an interpretation of over 100,000 variants according to the ACMG guideline (15) and prioritizes variants. 3 Billion created a symptom suggestion system based on Human Phenotype Ontology (HPO), which increases probability of capturing all of the patient's symptoms. Finally, the system scored similarity between clinical symptoms caused by prioritized variants and patient's phenotype. And the score was matched with plausible genetic diagnosis listed in OMIM data base.
This study was to investigate diagnostic yield and clinical utility of our new software that assists clinicians with diagnosis of patients with suspected genetic disorders.
Materials and Methods

Recruitment of patients
The study enrolled a total of 194 patients with clinically suspicion of genetic disorder, non- In all cases, the SureSelect Human All Exon V6 probe set was used. Exome capture was performed according to the standard Agilent SureSelect Target Enrichment protocol. The captured DNA was then amplified. The final purified product is then quantified using qPCR according to the qPCR Quantification Protocol Guide and qualified using the TapeStation DNA screentape (Agilent). And then we sequenced using the NovaSeq platform (Illumina,San Diego, USA).
Paired-end sequences produced by HiSeq Instrument are firstly mapped to the human genome, where the reference sequence is UCSC assembly hg19 (original GRCh37 from NCBI, Feb.
2009), without unordered sequences and alternate haplotypes, using the mapping program 'BWA' (version 0.7.12), and generated a mapping result file in BAM format using 'BWA-MEM'. Then, we applied programs packaged in Picard-tools (ver.1.130) in order to remove PCR duplicates reducing those reads identically match to a position at start into a single one, using MarkDuplicates.jar, which requires reads to be sorted. The local realignment process is performed to consume BAM files and to locally realign reads such that the number of mismatching bases is minimized across all the read. Base quality score recalibration and local realignment around indels were performed using Genome Analysis Toolkit to locally realign reads such that the number of mismatching bases is minimized across all the read. 
Prioritization of variants and symptom suggestion system
Variants with minor allele frequencies less than 0.05% for dominant disease association or 2% for recessive disease association in population genome databases including gnomAD 
Variant interpretation and confirmation
Variants were interpreted based on our new software and patient's phenotype by medical geneticists and a clinical geneticist. Finally, physician in the outpatient clinic ordered sanger sequencing to patients and their parents after one more examination in outpatient clinic. 8 All statistical analyses were performed with R studio (version 3.
Statistical analysis
5.1). To analyze principal
Component Analysis (PCA) of symptom and genetic variation, patient symptom matrix was constructed to have 1 as an entry (i, j) if a patient j has symptom i, and 0 otherwise. Genetic variation matrix has 1 as an entry (i, j) if a patient j has variant i. All pathogenic variants aggregated from total patients were used. 10 types of functional type of variation were treated separately to make 1285 combination of gene and functional variant types of pathogenic variation. The two major principal components of patient symptom matrix and genetic variation matrix were calculated by custom made program using Eigen C++ linear algebra library.
Results
Patients demographics
Basic demographic characteristics were noted in Table 1 . The mean age at presentation and performed WES of the patients was 6.8 ± 13.3 (range, 0 -68 years) and 10.2 ± 14.7 years (range, 0 -70 years), respectively. One hundred-fifty-three patients (78.8%) were under 10 years of age. Patients showed wide range of clinical manifestations, described by 25 high HPO categories. The average number of overlapping HPO categories per patient was 8.1 ± 5.0. The most common HPO category was nervous system (63.9%), followed by head and neck (46.9%), skeletal (44.8 %), cardiovascular (33%), eye (29.4%), and others were noted in Table 1. A 145 patients (74.7%) in this study were done genetic testing before WES. Targeted exome sequencing (included 4813 OMIM genes) and array comparative genome hybridization were performed in 24 patients and 5 patients, respectively, which revealed no diagnostic variants. Table 1 ). Fifty-five novel variants were identified.
The most common HPO category in patients with genetic diagnosis was nervous system (64.9%), followed by head and neck (42.6%), skeletal (42.6%), musculature (30.9%), and cardiovascular (29.8%), which was similar with those of total patients (Figure 2A ). More than 30% of most phenotypes were related to diagnosis, of which abnormality of connective tissue was 57.1% ( Figure 2B ). There was no significant difference in the average number of HPO categories between undiagnosed and diagnosed patients (8.6 ± 5.1 vs. 7.4 ± 5.7, P = 0.158). In Figure 3A , when the patients were distributed based on the patient's symptoms, the rightcentered portion indicated patients with similar symptoms. There was no significant difference in the distribution of clinical symptoms between the patients who were diagnosed with and without genetic disorder (by 2-dimensional Kolmogorov-Smirov test). Similarity of principal component (PC1) value in symptom principal component analysis (PCA) of two patients implies symptom similarity of the patients. By visual inspection of Figure 3B , we divided patients into two groups using 0.75 of PC1 in symptom PCA value as a threshold. Eighty-six patients out of 194 (44%) were grouped together in PC1 of symptom PCA range from 1.03 to 0.75 (9% of total symptom PCA PC1 length). In other words, 44% of total patients filled only 9% of total symptom PCA space, and the remaining 56% of patients filled the other 91% of symptom PCA space. The two patient groups had similar genetic variant diversities (P = 0.899 by Student's t-test of PC1 values of genetic variation PCA). showed lactic acidosis and hyperbilirubinemia at birth and initial mitochondrial genome test was negative. Because of high lactate level in serum, she was on ketogenic diet. After WES, she was diagnosed with pyruvate carboxylase deficiency caused by c.180delinsGC and c.2875delinsGT of PC gene and stopped ketogenic diet. She started high carbohydrate diet, which lead to improvement of biochemical findings.
Impact on clinical management after genetic diagnosis
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Discussion
WES has been used to find genetic causes in a large population of patients with autism, epilepsy, neurodevelopmental delay, hearing loss, and congenital heart disease, and it has effectively identified many novel genes and has suggested mechanism (3-10). In particular, patients who had hearing problem, visual impairment, or abnormality of musculoskeletal system, or patients being critical condition or presenting symptom at newborn period showed higher diagnostic yield (over 50%) compared with that of other patients (4, 8, 18) . However, researchers find diagnostic process exhausting because WES takes large amount of time to interpret a vast amount of variants, even though the clinical utility of WES has been clearly shown in various studies (6, 11) . We developed an automated interpretation system for the whole process of WES including raw data processing, variant calling, variant interpretation, and measurement of phenotypic similarity between the patient and each disease. There were initially more than 100,000 variants identified from WES, around 25,000 variants were remained after filtering out variants without association of disease. About 1,000~1,100 variants were classified as pathogenic, likely pathogenic or uncertain significance with estimation of pathogenicity according to ACMG guideline (15) . Fewer than 20 variants with significant similarity between associated disease and patient's phenotypes remain for clinical confirmation by medical geneticists. The whole workflow before final confirmation by clinicians is all processed automatically, which reduces the total amount of time for the diagnostic process from 20~40 hours to less than 20 minutes with a detection rate as high as that reported in previous study (11) . This present study showed improved diagnostic yield despite including patients with clinical heterogeneity and varying age, which means this newly introduced system is more effective than the traditional bioinformatics tools, and especially reduces time to calculate pathogenicity for a number of variants and correlate patient's phenotype with genotype. The 13 diagnostic odyssey left emotional exhaustion for the uncertainty of diagnosis and high cost for several investigations including biochemical tests, imaging tests, and genetic tests (19) .
According to a survey of patients with genetic disease in Europe, 25% of patients took a broad diagnostic period of 5 to 30 years from presenting symptom to receiving a definitive diagnosis (20) . Forty percent of these patients were misdiagnosed during that period, leading to inappropriate intervention and unsatisfactory genetic counselling (20) . The most common contributing factor for patients not receiving a genetic diagnosis prior to WES was significant genetic heterogeneity and phenotypic diversity associated with their disorders (21) . Recent study for infants with a suspected monogenic disorder performed singleton WES without pregenetic tests, showing high diagnostic yield and impact on clinical management (8) . In this present study, no difference in detection rate and diagnostic duration was found for patients with or without previous genetic tests. Furthermore, genetic heterogeneity was identified among patients with similar symptoms, even though clinician suspected specific disorders that were well known to match with their phenotypes. Thus, WES as a first-tier option for undiagnosed patients would be clinically valid and cost-effective to be performed at patient's first visit without other genetic tests such as chromosomal microarray, targeted panel, or clinical exome sequencing.
Although the number of patients older than 10 years old in this cohort was smaller than that of patients under 10 years old, diagnostic rate in the former population was higher than that in the latter one. The diagnosis for patients older than 10 years was associated with abnormality of connective tissue, kidney, eye, or musculoskeletal system, which was consistent with the fact that they showed fewer phenotypes than patients under 10 years old. This may be associated with having a specific phenotype in the case of diseases that develop symptoms as the patient ages, which can contribute to a high diagnostic yield in older patients.
14 For all patients for whom a diagnosis was made, clinicians may receive accurate prognostic information to provide future reproductive genetic counselling and management to their families. Depending on both the diagnostic period and cohort characteristics, the percentage of patients whose clinical management has changed varied from 5% to 65% (8, 18, 21) . About 30% of patients with genetic diagnosis in this study had a change in clinical management after WES. Three patients changed or stopped medication and one patient modified diet therapy.
Twenty-nine patients had additional investigation related to known clinical course. Ultimately, the benefits of genetic diagnosis confirmed by molecular test can be extended beyond the direct management of patients and influence long term clinical course.
Several limitations of the study should be addressed. First, about 11% of reported variants failed Sanger confirmation in this study despite a few variants had sufficient quality score (data not shown) and matched patient's phenotype. Technical issue of WES is still major limitation of detection rate of WES for diagnosis of rare disease. The accuracy of WES has been improved with development of bioinformatics tools and genetic method, allowing to empirically be determined quality score (>500) for identified variant that do not require Sanger confirmation (22) . However, even with non-stringent criteria applied to whether or not to perform Sanger sequencing, 13% of the variants failed the sanger confirmation and 8.3% of them are unpredictable (23) . There is still no clear criteria or method to predict which variants need further confirmation of variant, thus leading to need of additional validation of raw read depth and allele fraction by WES. Second, when groups were categorized by age, the total number of patients in each group was different. Third, twenty of patients with genetic diagnosis (20/94) did not performed segregation analysis due to definite family history, full matched phenotype, or absence of parents. Incomplete penetrance was not considered in these patients.
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In conclusion, WES with an automated interpretation system showed high diagnostic yield, providing a definitive diagnosis to 48.4% of patients with clinical heterogeneity. Variants of different genes were identified in patients with similar phenotypes. Clinical management such as medication change and long-term surveillance had impact on patients with genetic diagnosis.
Therefore, WES can be used as a first diagnostic method for patients presenting diverse symptoms involving the multidisciplinary system as well as patients with suspected specific disorders. However, studies on application of even more advanced platform are needed because clinical confirmation of identified variants and associated disorders still remains as a process that is not only time-consuming but also susceptible to error, which increases false results. 
